Cargando…
Use of the XRCC2 promoter for in vivo cancer diagnosis and therapy
The homologous recombination (HR) pathway is a promising target for cancer therapy as it is frequently upregulated in tumors. One such strategy is to target tumors with cancer-specific, hyperactive promoters of HR genes including RAD51 and RAD51C. However, the promoter size and the delivery method h...
Autores principales: | Chen, Yu, Li, Zhen, Xu, Zhu, Tang, Huanyin, Guo, Wenxuan, Sun, Xiaoxiang, Zhang, Wenjun, Zhang, Jian, Wan, Xiaoping, Jiang, Ying, Mao, Zhiyong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5856804/ https://www.ncbi.nlm.nih.gov/pubmed/29549248 http://dx.doi.org/10.1038/s41419-018-0453-9 |
Ejemplares similares
-
Base excision repair but not DNA double‐strand break repair is impaired in aged human adipose‐derived stem cells
por: Zhang, Haiping, et al.
Publicado: (2019) -
The deacetylase SIRT6 promotes the repair of UV-induced DNA damage by targeting DDB2
por: Geng, Anke, et al.
Publicado: (2020) -
Single senescent cell sequencing reveals heterogeneity in senescent cells induced by telomere erosion
por: Tang, Huanyin, et al.
Publicado: (2018) -
A PARP1–BRG1–SIRT1 axis promotes HR repair by reducing nucleosome density at DNA damage sites
por: Chen, Yu, et al.
Publicado: (2019) -
Significant value of XRCC2 and XRCC9 expression in the prognosis of human ovarian carcinoma
por: Liu, Yi, et al.
Publicado: (2021)